FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2183601402> ?p ?o ?g. }

• W2183601402 endingPage "25" @default.
• W2183601402 startingPage "117" @default.
• W2183601402 abstract "tibolone at usual doses of 2.5 mg/day in postmenopausal women has been shown to improve climacteric complaints, without affecting endometrial thickness and lipid profile or blood glucose. However, the potentially similar efficacy, but better tolerability, of a low dose of this drug (1.25 mg) has never been established.162 healthy, non-obese, post-menopausal women, aged 40-65 years, with an intact uterus were enrolled in a national, single centre, randomised, double blind, placebo controlled, parallel group trial. After 1 week of runin, patients were treated for 24 weeks with placebo, tibolone 1.25 mg or 2.5 mg/day. During the study laboratory tests, endometrial ultrasound scans and mammography were performed. Occurrence of menopausal signs and symptoms, including vaginal bleeding, and quality of sexual life were also checked.in the 120 patients terminating the study without major protocol violations, climacteric symptoms were similarly improved by tibolone 1.25 and 2.5 mg (78% and 90% reduction at week 24 for hot flushes, 36% and 34% for sweating episodes and 44% and 51% for vaginal dryness), but not by placebo. Benefits occurred earlier in the group treated with tibolone 2.5 mg. Quality of sexual life was almost invariably improved by tibolone as compared to placebo, but improvement occurred earlier in the tibolone 1.25 mg group. Severity of vaginal bleeding was not different between placebo and active treatment groups, except at week 12 when was higher. At the end of treatment vaginal bleeding occurred in 15% of patients treated with placebo, 14% treated with tibolone 1.25 mg and 12% treated with tibolone 2.5 mg. Endometrial thickness and breast density were not changed by treatment, as well as FSH, 17-beta-estradiol, total cholesterol, HDL and LDL cholesterol, triglycerides and blood glucose. Adverse events were reported by 14.7%, 26.7% and 24.4% of patients treated with placebo, tibolone 1.25 mg and tibolone 2.5 mg/day, respectively.tibolone at doses of 1.25 or 2.5 mg/day given for 24 weeks to postmenopausal women displayed similar efficacy and safety profiles, though were more effective than placebo. Tibolone 1.25 mg induced a more gradual relief from climacteric symptoms and a more prompt improvement of sexual function." @default.
• W2183601402 created "2016-06-24" @default.
• W2183601402 creator A5036414398 @default.
• W2183601402 creator A5068342391 @default.
• W2183601402 creator A5084469856 @default.
• W2183601402 creator A5085353911 @default.
• W2183601402 date "2004-06-25" @default.
• W2183601402 modified "2023-10-18" @default.
• W2183601402 title "Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women." @default.
• W2183601402 cites W1966837680 @default.
• W2183601402 cites W1983630208 @default.
• W2183601402 cites W1991376015 @default.
• W2183601402 cites W1993887499 @default.
• W2183601402 cites W1994913342 @default.
• W2183601402 cites W2001535314 @default.
• W2183601402 cites W2009774734 @default.
• W2183601402 cites W2012974823 @default.
• W2183601402 cites W2013093446 @default.
• W2183601402 cites W2018219851 @default.
• W2183601402 cites W2020796252 @default.
• W2183601402 cites W2033219375 @default.
• W2183601402 cites W2037649734 @default.
• W2183601402 cites W2043222887 @default.
• W2183601402 cites W2044383337 @default.
• W2183601402 cites W2058207289 @default.
• W2183601402 cites W2060269207 @default.
• W2183601402 cites W2065660647 @default.
• W2183601402 cites W2069878676 @default.
• W2183601402 cites W2071023751 @default.
• W2183601402 cites W2083128744 @default.
• W2183601402 cites W2083733820 @default.
• W2183601402 cites W2099684984 @default.
• W2183601402 cites W2106490260 @default.
• W2183601402 cites W2124454568 @default.
• W2183601402 cites W2142799199 @default.
• W2183601402 cites W2162238066 @default.
• W2183601402 cites W2162402859 @default.
• W2183601402 cites W2166858334 @default.
• W2183601402 cites W2395035696 @default.
• W2183601402 cites W2414649790 @default.
• W2183601402 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15214586" @default.
• W2183601402 hasPublicationYear "2004" @default.
• W2183601402 type Work @default.
• W2183601402 sameAs 2183601402 @default.
• W2183601402 citedByCount "4" @default.
• W2183601402 countsByYear W21836014022016 @default.
• W2183601402 countsByYear W21836014022023 @default.
• W2183601402 crossrefType "journal-article" @default.
• W2183601402 hasAuthorship W2183601402A5036414398 @default.
• W2183601402 hasAuthorship W2183601402A5068342391 @default.
• W2183601402 hasAuthorship W2183601402A5084469856 @default.
• W2183601402 hasAuthorship W2183601402A5085353911 @default.
• W2183601402 hasConcept C126322002 @default.
• W2183601402 hasConcept C142724271 @default.
• W2183601402 hasConcept C197934379 @default.
• W2183601402 hasConcept C198454886 @default.
• W2183601402 hasConcept C204787440 @default.
• W2183601402 hasConcept C27081682 @default.
• W2183601402 hasConcept C2777457466 @default.
• W2183601402 hasConcept C2778375690 @default.
• W2183601402 hasConcept C2778562196 @default.
• W2183601402 hasConcept C2779234561 @default.
• W2183601402 hasConcept C2780218171 @default.
• W2183601402 hasConcept C29456083 @default.
• W2183601402 hasConcept C54355233 @default.
• W2183601402 hasConcept C71924100 @default.
• W2183601402 hasConcept C86803240 @default.
• W2183601402 hasConceptScore W2183601402C126322002 @default.
• W2183601402 hasConceptScore W2183601402C142724271 @default.
• W2183601402 hasConceptScore W2183601402C197934379 @default.
• W2183601402 hasConceptScore W2183601402C198454886 @default.
• W2183601402 hasConceptScore W2183601402C204787440 @default.
• W2183601402 hasConceptScore W2183601402C27081682 @default.
• W2183601402 hasConceptScore W2183601402C2777457466 @default.
• W2183601402 hasConceptScore W2183601402C2778375690 @default.
• W2183601402 hasConceptScore W2183601402C2778562196 @default.
• W2183601402 hasConceptScore W2183601402C2779234561 @default.
• W2183601402 hasConceptScore W2183601402C2780218171 @default.
• W2183601402 hasConceptScore W2183601402C29456083 @default.
• W2183601402 hasConceptScore W2183601402C54355233 @default.
• W2183601402 hasConceptScore W2183601402C71924100 @default.
• W2183601402 hasConceptScore W2183601402C86803240 @default.
• W2183601402 hasIssue "5" @default.
• W2183601402 hasLocation W21836014021 @default.
• W2183601402 hasOpenAccess W2183601402 @default.
• W2183601402 hasPrimaryLocation W21836014021 @default.
• W2183601402 hasRelatedWork W1643798622 @default.
• W2183601402 hasRelatedWork W198195086 @default.
• W2183601402 hasRelatedWork W1998117916 @default.
• W2183601402 hasRelatedWork W2016765858 @default.
• W2183601402 hasRelatedWork W2019305460 @default.
• W2183601402 hasRelatedWork W2065239289 @default.
• W2183601402 hasRelatedWork W2074059519 @default.
• W2183601402 hasRelatedWork W2080271939 @default.
• W2183601402 hasRelatedWork W2082133635 @default.
• W2183601402 hasRelatedWork W2106799879 @default.
• W2183601402 hasRelatedWork W2154884249 @default.
• W2183601402 hasRelatedWork W2156552325 @default.

• next